In pharmaceutical patent litigation, the 180-day generic drug exclusivity is the ultimate prize. It is the “brass ring” 1, a […]

From Lagging Indicators to Leading Signals: The Strategic Imperative of Alternative Data For decades, investment decisions in the pharmaceutical and

The Core Thesis: Patents as the Currency of Biopharma Value The Grand Paradox of Biotech Valuation The world of biotechnology

The Strategic Imperative: Why Analyzing Patent Deals Is Your Competitive Advantage The pharmaceutical and biotech sectors operate at the confluence

The Strategic Crossroads of IP and Market Access Introduction: Beyond the Buzzword In the complex ecosystem of pharmaceutical intellectual property,

Introduction: Beyond the 20-Year Myth – The New Reality of Pharma Exclusivity For decades, the conventional wisdom in pharmaceutical investing

The Looming Precipice: An Introduction to the Patent Cliff Phenomenon For decades, the pharmaceutical industry has operated on a foundational

The Inherent Limitations of the Orange Book: A Foundation, Not a Fortress The U.S. Food and Drug Administration’s (FDA) Approved

Part I: The Dual Frameworks of Protection: Legal and Regulatory Foundations In the capital-intensive world of pharmaceutical innovation, intellectual property